openFDA Pricing: Cost and Access Details (2026)

Pricing overview

The openFDA API operates on a public access model, meaning there are no direct costs associated with its use. The U.S. Food and Drug Administration (FDA) provides openFDA as a free resource to facilitate public health research, innovation, and transparency. This model contrasts with many commercial APIs that employ tiered pricing, pay-per-use, or subscription-based structures. Users can query various datasets, including drug adverse events, device adverse events, and food adverse events, without incurring any financial charges or requiring an API key for authentication.

The absence of a pricing structure simplifies integration and adoption for developers, researchers, and organizations. The operational costs of openFDA are covered by federal funding as part of its mission to make FDA data more accessible. This enables unlimited access to historical and real-time public health data, subject only to general usage policies and soft rate limits designed to ensure fair access for all users. The openFDA API reference outlines the available datasets and query parameters without mentioning any associated costs, reinforcing its free-to-use nature.

Plans and tiers

openFDA does not offer distinct plans or pricing tiers. Unlike commercial API providers that often segment access based on usage volume, feature sets, or support levels, openFDA provides a single, unified access model for all users. This approach ensures equitable access to critical public health data for a wide range of stakeholders, from individual researchers to large institutional projects.

The lack of tiered plans means that all users receive the same level of API access and functionality. There are no premium features locked behind higher-cost tiers, nor are there different data freshness guarantees or support levels based on payment. This flat-access model aligns with the FDA's goal of maximizing data dissemination for public benefit, avoiding potential barriers that tiered pricing might introduce. The official openFDA API documentation confirms the absence of commercial plans or subscription options.

Here is a summary of the single access model:

Free tier and limits

The entirety of the openFDA API can be considered a free tier, as there are no paid options. Users can access all available datasets, including drug adverse events, medical device reports, and food recall data, without any financial commitment. This comprehensive free access is a core feature of the openFDA initiative, designed to lower barriers to entry for data-driven public health initiatives.

While openFDA is free, it does implement soft rate limits to ensure fair usage and maintain service stability for all users. These limits are not designed to restrict access for typical research or application development but rather to prevent abuse or excessive load on the system. Current soft limits, as detailed in the official documentation, include:

• Requests per minute: Approximately 1,000 requests per minute.
• Records per query: Up to 100,000 records per query.
• Maximum offset: Queries are limited to an offset of 25,000 records, meaning users can retrieve records up to the 25,000th result in a paginated series. For larger datasets, users are advised to refine their queries or use the skip parameter carefully.

These limits are generally sufficient for most use cases, including data exploration, building prototypes, and even powering production applications that integrate FDA data. For users requiring significantly higher throughput or custom data extracts that exceed these soft limits, direct engagement with the FDA through official channels might be necessary, though this typically involves specific data sharing agreements rather than a commercial pricing model.

Real-world cost examples

Given openFDA's fully free pricing model, the real-world cost examples are straightforward: there are no direct costs for using the API itself. Any expenses incurred would be related to the user's own infrastructure, development time, or third-party services integrated with openFDA data, rather than fees charged by the FDA.

Here are a few scenarios:

• Academic Researcher: A university researcher developing a model to predict drug adverse event trends. They make thousands of API calls daily to retrieve historical drug adverse event data and new reports. Their direct cost for openFDA API access: $0. Their costs might include cloud computing resources for data processing (e.g., Google Cloud Compute Engine), storage for the retrieved data, and their own labor.

• Startup Building a Drug Safety Dashboard: A small startup creates a public dashboard visualizing medical device recall data. They query openFDA hourly to keep their dashboard updated. Their direct cost for openFDA API access: $0. Their expenses would be for web hosting (e.g., AWS S3 for static content, or Azure App Service), front-end development, and potentially a database to store aggregated data.

• Healthcare Provider Integrating Data: A hospital system wants to integrate drug labeling information into their electronic health records (EHR) system for quick reference. They make occasional API calls to retrieve specific drug labels. Their direct cost for openFDA API access: $0. Their primary costs would be for the development and maintenance of the integration layer within their existing EHR infrastructure.

• Non-profit Consumer Advocacy Group: A non-profit organization develops a mobile app that allows consumers to look up food recalls by product name. The app queries the openFDA food recall API on demand. Their direct cost for openFDA API access: $0. Costs would involve app development, mobile app store fees, and potentially serverless functions (e.g., Firebase Functions) to proxy requests or handle data processing.

In all these scenarios, the core data access from openFDA remains free, allowing organizations of all sizes and budgets to leverage critical public health information without incurring API-related fees.

How the pricing compares

The openFDA API's fully free model distinguishes it significantly from most commercial data APIs and even other government-provided data services that may have indirect costs or stricter usage policies. When comparing openFDA's pricing, several aspects stand out:

• Commercial Data Providers: Many platforms offering curated or aggregated healthcare and life sciences data, such as those providing clinical trial data, pharmaceutical market intelligence, or detailed adverse event reports from proprietary sources, typically operate on subscription models, per-record fees, or enterprise licensing. These can range from hundreds to thousands of dollars per month or year, depending on the scope of data and usage. openFDA, by contrast, offers its core public data at no charge, making it an accessible starting point for many projects.

• Cloud Provider Data Marketplaces: Cloud platforms like AWS, Google Cloud, and Azure offer data marketplaces where third-party datasets, including some related to healthcare, can be purchased. These often involve usage-based pricing on top of the cloud infrastructure costs. While highly scalable, they come with explicit data acquisition costs not present with openFDA.

• Other Government APIs: While many government APIs are free, some may require an API key for higher rate limits or offer premium tiers for commercial use cases. For example, certain APIs from the Centers for Disease Control and Prevention (CDC) or other federal agencies might have different access policies, though many also follow a free public access model. openFDA's clear stance on being entirely free with soft limits is a consistent benefit.

• Proprietary Data Aggregators: Companies that aggregate, clean, and standardize public FDA data, often combining it with other sources, may charge for their enhanced datasets or API access. While they might offer value-added services like data normalization or advanced analytics, openFDA provides the raw, official data directly from the source for free, allowing users to perform their own processing.

In summary, openFDA's pricing model is highly competitive because it eliminates the cost barrier entirely. This makes it particularly attractive for academic research, non-profit initiatives, and startups operating on limited budgets, providing a foundational source of FDA public health data without direct financial overhead.